RxDoctor Payments Data

Melissa Graves

Family · Sevierville, TNNPI 1235375494

Payments from drug & device makers

$11,698in general payments, 2019–2025

Across 552 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$949
  • Corcept Therapeutics$775
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
  • GSK$684
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$11,60699%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,698 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,721
Medicare patients
99
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$95,145
FarxigaDapagliflozin Propanediol61$63,155
TrulicityDulaglutide33$48,932
EliquisApixaban44$44,438
LinzessLinaclotide34$41,861
JardianceEmpagliflozin18$32,372
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$28,721
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,261
XareltoRivaroxaban19$18,879
MounjaroTirzepatide18$18,150
BrilintaTicagrelor12$6,736
JanuviaSitagliptin Phosphate12$6,434
LantusInsulin Glargine,hum.Rec.Anlog33$5,524
DiovanValsartan12$4,276
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen166$3,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$949$95,14574 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,115$89,151103 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$289$69,36967 claims
PfizerEliquis$122$44,43844 claims
AbbVieLinzess, Synthroid$1,600$43,11749 claims
Boehringer IngelheimJardiance$245$32,37218 claims
GSKTrelegy Ellipta$684$28,72132 claims
MerckJanuvia$56$6,43412 claims
Sanofi-aventis U.S. LLCLantus$22$5,52433 claims
NovartisDiovan$37$4,27612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Sevierville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →